A5031689930- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Electrolyte and hormonal disorders
- Cancer therapeutics and mechanisms
- Neuroblastoma Research and Treatments
- Viral-associated cancers and disorders
- Intraperitoneal and Appendiceal Malignancies
- Chemotherapy-induced organ toxicity mitigation
- Lung Cancer Treatments and Mutations
- Pancreatitis Pathology and Treatment
- Acute Myeloid Leukemia Research
- Chemotherapy-related skin toxicity
- Pancreatic and Hepatic Oncology Research
- Gestational Trophoblastic Disease Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Pancreatic function and diabetes
- Neuropeptides and Animal Physiology
- Sarcoidosis and Beryllium Toxicity Research
- Bone health and treatments
- Colorectal Cancer Treatments and Studies
- Chromatin Remodeling and Cancer
- Chemical Synthesis and Analysis
Bispebjerg Hospital
1985-2025
University of Copenhagen
1988-2025
Rigshospitalet
1981-1998
University College Capital
1993-1996
Utrecht University
1993
Herlev Hospital
1986-1990
Copenhagen University Hospital
1986-1990
Regionshospitalet Viborg
1990
Hvidovre Hospital
1990
A consecutive group of 259 patients with inoperable adenocarcinoma the lung (ACL) were observed to define risk groups for and frequency brain metastases together prognosis. All received chemotherapy in a three-armed randomized trial. Brain diagnosed 25 before protocol entry 37 during treatment. autopsy was performed 87 positive 38 (44%). Eleven these (29%) not clinically. Patients younger than 60 years had somewhat higher overall older patients. initial performance status above 60%...
PURPOSE To describe in patients with small-cell lung cancer (SCLC) the characteristics of those who survive for > or = 5 years, to identify long-term prognostic factors, analyze survival data 5-year survivors, and study 10-year entered before 1981. PATIENTS AND METHODS A total 1,714 unselected SCLC were treated combination chemotherapy nine consecutive clinical trials from 1973 1991. All medical records reviewed follow-up obtained compare pretreatment posttreatment characteristics....
The influence of treatment and pretreatment patient characteristics on the probability long-term disease-free survival in small-cell lung cancer (SCLC) was investigated a consecutive series 874 patients. patients were included six controlled trials from 1973 to 1981, using different combinations chemotherapy with or without irradiation. All underwent staging, including bronchoscopy, peritoneoscopy liver biopsy, bone marrow examination. same procedures repeated overt signs disease 18 months...
PURPOSE To report five cases of acute monocytic or myelomonocytic leukemia after chemotherapy with 4-epidoxorubicin for breast cancer and to evaluate the risk use this drug. PATIENTS AND METHODS One hundred fifty-seven patients advanced were randomized either 4-epi-doxorubicin plus cisplatin alone. An additional 203 treated prospectively All observed closely leukemic complications. RESULTS Three from study developed leukemia; all in subgroup 74 who received cisplatin, whereas no was among...
The cardiotoxicity of epirubicin (EPI) was evaluated clinically, radiologically, with ECG, and multiple ECG-gated radionuclide determination the left ventricular ejection fraction (LVEF) during rest in 135 patients advanced breast cancer. EPI doses were 60 mg/m2 on days 1 8 every 4 weeks or 45 plus vindesine 3 same schedule. median cumulative dose 500 (range, 47 to 1,563). Eight developed congestive heart failure (CHF). Of 67 treated less than mg/m2, none CHF. Among 48 between 1,000 one had...
INTRODUCTION: Opioids used to manage severe pain in acute pancreatitis (AP) might exacerbate the disease through effects on gastrointestinal and immune functions. Methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, may counteract these without changing analgesia. METHODS: This double-blind, randomized, placebo-controlled trial included adult patients with AP systemic inflammatory response syndrome at 4 Danish centers. Patients were randomized receive 5 days of continuous...
Dysmotility is common in acute pancreatitis (AP) and may be evaluated using radiopaque markers imaging. We present a simple CT-based approach, which was employed hospitalized patients with AP. This secondary analysis of randomized, controlled trial conducted at four Danish centers. Patients admitted AP systemic inflammatory response syndrome were randomized to receive 5 days intravenous methylnaltrexone or placebo (lactated ringer) added standard management. Self-reported stool frequency...
Teniposide, VM-26 (Vumon), was administered in a dose of 60 mg/m2 on days 1 to 5 every third week 36 patients with histologically confirmed small-cell lung cancer. None had previously received chemotherapy or radiotherapy. The median age 73 years (range, 52 79). Thirty-three were evaluable; 21 these local disease. Five bone marrow metastases, four liver involvement, and one CNS metastases. All performance status less than equal 2 before the start treatment. Thirty obtained response (90%),...
A phase II trial of carboplatin, 300 mg/m2 day 1, and cisplatin, 50 days 2 3 every 4 weeks for six cycles, was performed in 42 previously untreated patients with residual disease after primary laparotomy. Overall, 79% had tumor larger than cm. The overall pathologic response rate (pathologic complete [PCR] plus partial [PPR]) 37 evaluable 62%, PCRs 22%. Of the responding patients, 78% toxicity cumulative but manageable, thrombocytopenia being main reason dose reduction. Dose-limiting...
Mortality and morbidity was investigated in a consecutive series of 72 patients with small-cell lung cancer (SCLC) who were found to be disease-free at restaging after 18 months treatment. These all the long-term survivors among 874 included one six trials between 1973 1981. All studies used combination chemotherapy or without irradiation. Follow-up varied 4 11 years. The estimated 5-year survival rate subsequent discontinuation therapy 0.24, corresponding death 0.25 per year ten times...
Two hundred and eighty-eight patients with extensive small-cell carcinoma of the lung (SCCL) were entered into a three-arm prospective randomized trial. The purpose was both to compare etoposide methotrexate (MTX) in combination chemotherapy regimen otherwise consisting vincristine (VCR), lomustine (CCNU), cyclophosphamide (CTX) evaluate treatment design based on cell kinetic observations suggesting enhanced sensitivity three six days after administration VCR, CCNU, CTX. In all arms, CTX...
A randomized study comparing teniposide (VM-26) and etoposide (VP-16) was performed to investigate whether there are any differences in the activity toxicity of these two analogs small-cell lung cancer (SCLC). Only previously untreated patients with SCLC were included; 46 48 receiving VP-16 VM-26, respectively, assessable for response. There no between groups respect extent disease, median age, performance status (PS). The initial doses both compounds 70 mg/m2 intravenously (IV) daily 5 days...
Two hundred seventy-nine patients with previously untreated nonresectable adenocarcinoma of the lung (ACL) entered a prospective randomized trial, comparing vindesine (VDS) to combination lomustine (CCNU), cyclophosphamide (CTX), and methotrexate (MTX), regimen including all four drugs. Response assessment was possible in 218 patients, while 259 were evaluable for survival. rates similar (22%, 23%, 27%, respectively) as median durations response (15 weeks overall) survival (29 overall)....
Many small-cell lung cancers (SCLCs) produce gastrin-releasing peptides (GRPs) (mammalian bombesin) but the plasma concentration of GRP is rarely elevated, possibly because its rapid elimination. We developed a radioimmunoassay for C-terminal flanking peptide proGRP and measured in from 71 patients with SCLC, 27 healthy subjects 49 other diseases including carcinomas. In addition, we studied molecular size immunoreactive C-flanking two SCLC cell lines patients. The normal control did not...
A therapeutic policy of surgery in the treatment small cell carcinoma lung was evaluated a retrospective series 874 consecutive patients. All patients were included one six clinical trials intensive combination chemotherapy and radiotherapy, carried out during 1973-81. General criteria resectability, including normal appearances at mediastinoscopy, fulfilled 33 electively operated 46 non-operated An elective operation defined as thoracotomy performed with intention pulmonary resection...
Carboplatin 200 mg/m2 day 1, cisplatin 50 days 2 and 3, ifosfamide 1,500 1 to mesna 900 3 every 4 weeks for six cycles were given 37 previously untreated ovarian cancer patients with residual disease after the primary laparotomy. The median observation time was 17+ months (range, 9+ 24+ months). Of all patients, 81% had larger than cm. overall pathologic response rate (pathologic complete [PCR] plus partial [PPR]) in 36 assessable 58%, PCR 42%. 53% tumor 5 substantial hematologic toxicity...
Gemcitabine has activity in advanced ovarian cancer, with responses platinum-resistant disease. This study assessed the of gemcitabine previously untreated patients epithelial cancer. All had histologically verified invasive International Federation Gynecology and Obstetrics (FIGO) stage III/IV disease no prior chemotherapy. Patients received 1250 mg/m2 on days 1, 8 15 a 28-day cycle. Radiological response was after two cycles. Between December 1992 October 1995, 35 were enrolled. Of 33...